期刊论文详细信息
International Journal of Molecular Sciences
Anti-Vascular Endothelial Growth Factor Therapy inBreast Cancer
Elisabeth Warnke1  Markus Wehland1  Tina Bøgelund Kristensen2  Daniela Grimm2  Malin L. T. Knutsson2  Britt Elmedal Laursen3  Nils E. Magnusson4 
[1] Clinic for Plastic, Aesthetic and Hand Surgery, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, Magdeburg D-39120, Germany;Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers Allé 4,Aarhus C 8000, Denmark;Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, Aarhus C 8000, Denmark;Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Nørrebrogade 44, Aarhus C 8000, Denmark;
关键词: breast cancer;    anti-angiogenic therapy;    biomarkers;    vascular endothelialgrowth factor;   
DOI  :  10.3390/ijms151223024
来源: DOAJ
【 摘 要 】

Neo-angiogenesis is a critical process for tumor growth and invasion and has become a promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial growth factor system: bevacizumab, ramucirumab and sorafenib. The efficacy of anti-angiogenic drugs in adjuvant therapy or as neo-adjuvant treatment has been estimated in clinical trials of advanced breast cancer. To date, the overall observed clinical improvements are unconvincing, and further research is required to demonstrate the efficacy of anti-angiogenic drugs in breast cancer treatments. The outcomes of anti-angiogenic therapy have been highly variable in terms of tumor response. New methods are needed to identify patients who will benefit from this regimen. The development of biomarkers and molecular profiling are relevant research areas that may strengthen the ability to focus anti-angiogenic therapy towards suitable patients, thereby increase the cost-effectiveness, currently estimated to be inadequate.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次